Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Elicio Therapeutics, Inc. (ELTX)
USD3.04
-0.07 (-2.25%)
US NASDAQ Healthcare Biotechnology
Address
451 D Street 2210
Boston, MA, US
Boston, MA, US
CEO
Robert T. Connelly
Website
elicio.com
IPO
2021-02-05
CIK 1601485 ISIN US28657F1030
Description
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
News Sentiment (7d)
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.04
-0.07 (-2.25%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
1.44
Float Shares
8.72M
Free Float %
46.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -9.13% | +0.96% | +3.94% | +25.45% | +14.80% | +32.54% | +91.12% | +79.12% | +79.12% | +79.12% | +79.12% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
3.04
Low
17.00
+459.2%
Consensus
17.00
+459.2%
Median
17.00
+459.2%
High
17.00
+459.2%
DCF (Unlevered)
0.22
-92.6%
DCF (Levered)
0.26
-91.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 2 |
17.00
+459.2%
|
| Last Year | 2 |
17.00
+459.2%
|
| All Time | 3 |
11.83
+289.1%
|
Quality scores
Altman Z-Score
-14.70
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
2 / 5
Medium
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+39.3% ★ Q1'26: +25.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+25.5% Q1'26: +40.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.40× Q1'26: -0.11× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 EPS Ana. |
Dec 2028 1 EPS Ana. |
Dec 2029 1 EPS Ana. |
Dec 2030 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.88M
est: 2.98M (-3.4%)
|
28.31M
est: 9.79M (+189.2%)
|
—
est: 2.30M (-100.0%)
|
—
|
—
|
20.00M
20.00M – 20.00M
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBITDA |
-70.63M
est: 596.1K (-11,949.2%)
|
-51.93M
est: 1.96M (-2,752.3%)
|
-23.55M
est: 460.0K (-5,220.4%)
|
-50.27M
|
-36.59M
|
12.00M
12.00M – 12.00M
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-71.26M
est: 596.1K (-12,054.6%)
|
-52.73M
est: 1.96M (-2,793.3%)
|
-24.61M
est: 460.0K (-5,450.2%)
|
-51.44M
|
-37.71M
|
12.00M
12.00M – 12.00M
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-80.11M
est: -651.95M (+87.7%)
|
-26.40M
est: -342.90M (+92.3%)
|
-28.21M
est: -157.42M (+82.1%)
|
-51.90M
est: -49.54M (-4.8%)
|
-39.57M
est: -38.36M (-3.2%)
|
-24.88M
-24.88M – -24.88M
+35.1% YoY
|
-22.51M
-22.51M – -22.51M
+9.5% YoY
|
-26.95M
-26.95M – -26.95M
-19.7% YoY
|
-31.39M
-31.39M – -31.39M
-16.5% YoY
|
-32.31M
-32.31M – -32.31M
-2.9% YoY
|
| SGA |
17.46M
est: 5.78M (+202.2%)
|
17.78M
est: 18.97M (-6.3%)
|
5.63M
est: 4.46M (+26.3%)
|
11.33M
|
12.81M
|
18.51M
18.51M – 18.51M
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.93
est: -53.43 (+96.4%)
|
-19.32
est: -28.10 (+31.2%)
|
-9.10
est: -12.90 (+29.5%)
|
-4.25
est: -4.07 (-4.6%)
|
-2.58
est: -2.51 (-3.0%)
|
-1.63
-1.63 – -1.63
+35.1% YoY
|
-1.47
-1.47 – -1.47
+9.5% YoY
|
-1.76
-1.76 – -1.76
-19.7% YoY
|
-2.05
-2.05 – -2.05
-16.5% YoY
|
-2.11
-2.11 – -2.11
-2.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-38.48M
OE per share TTM
-2.30
Owner's Yield
-18.20%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
124.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
10
Total invested
1.43M
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
10
-30 vs prev Q
New positions
3
Closed positions
32
Increased
5
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | KNOLL CAPITAL MANAGEMENT, LLC | 630.9K +— (+0.0%) | 5.02M -1.9M (-27.2%) | 3.78% -0.149 pp | 2.30% -1.395 pp | USD6.16 +29.2% | 4 qtrs — |
| 2 | VANGUARD GROUP INC | 496.9K +23.0K (+4.9%) | 3.96M -1.2M (-23.7%) | 2.98% +0.026 pp | 0.00% +0.000 pp | USD6.90 +15.4% | 11 qtrs — |
| 3 | SIO CAPITAL MANAGEMENT, LLC | 296.9K +296.9K (+100.0%) | 2.36M +2.4M (+100.0%) | 1.78% +1.779 pp | 0.37% +0.372 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 4 | BALYASNY ASSET MANAGEMENT L.P. | 138.8K -9.3K (-6.3%) | 1.10M -515.4K (-31.8%) | 0.83% -0.091 pp | 0.00% -0.001 pp | USD10.94 -27.2% | 2 qtrs — |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 132.5K +2.8K (+2.2%) | 1.06M -364.1K (-25.7%) | 0.79% -0.014 pp | 0.00% +0.000 pp | USD6.84 +16.4% | 11 qtrs — |
| 6 | MARSHALL WACE, LLP | 117.2K +30.7K (+35.4%) | 932.9K -13.8K (-1.5%) | 0.70% +0.163 pp | 0.00% 0.000 pp | USD10.16 -21.7% | 2 qtrs — |
| 7 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 64.1K -56.2K (-46.7%) | 509.9K -805.2K (-61.2%) | 0.38% -0.365 pp | 0.00% 0.000 pp | USD10.26 -22.4% | 4 qtrs — |
| 8 | 683 CAPITAL MANAGEMENT, LLC | 56.4K +56.4K (+100.0%) | 449.3K +449.3K (+100.0%) | 0.34% +0.338 pp | 0.02% +0.020 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 9 | NORTHERN TRUST CORP | 52.8K -815.0 (-1.5%) | 420.0K -166.2K (-28.3%) | 0.32% -0.018 pp | 0.00% +0.000 pp | USD5.50 +44.7% | 7 qtrs — |
| 10 | STATE STREET CORP | 46.3K +8.0K (+20.9%) | 368.5K -50.5K (-12.0%) | 0.28% +0.039 pp | 0.00% +0.000 pp | USD8.34 -4.6% | 8 qtrs — |
| 11 | BLACKROCK, INC. | 45.2K +984.0 (+2.2%) | 359.6K -123.9K (-25.6%) | 0.27% -0.005 pp | 0.00% +0.000 pp | USD5.92 +34.5% | 6 qtrs — |
| 12 | CITADEL ADVISORS LLC | 35.2K +14.2K (+67.6%) | 280.2K +50.5K (+22.0%) | 0.21% +0.080 pp | 0.00% +0.000 pp | USD9.74 -18.3% | 2 qtrs — |
| 13 | UBS GROUP AG | 32.0K +25.0K (+356.1%) | 254.8K +178.1K (+231.9%) | 0.19% +0.148 pp | 0.00% +0.000 pp | USD7.71 +3.2% | 11 qtrs — |
| 14 | RENAISSANCE TECHNOLOGIES LLC | 28.1K -20.6K (-42.2%) | 223.8K -308.7K (-58.0%) | 0.17% -0.135 pp | 0.00% 0.000 pp | USD10.94 -27.2% | 2 qtrs — |
| 15 | CM MANAGEMENT, LLC | 25.0K +19.0K (+316.7%) | 199.0K +133.4K (+203.2%) | 0.15% +0.112 pp | 0.17% +0.113 pp | USD7.55 +5.4% | 11 qtrs — |
| 16 | OMERS ADMINISTRATION CORP | 23.5K +23.5K (+100.0%) | 187.1K +187.1K (+100.0%) | 0.14% +0.141 pp | 0.00% +0.001 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 17 | QUBE RESEARCH & TECHNOLOGIES LTD | 20.2K +20.2K (+100.0%) | 160.9K +160.9K (+100.0%) | 0.12% +0.121 pp | 0.00% +0.000 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 18 | QUADRATURE CAPITAL LTD | 17.2K +17.2K (+100.0%) | 136.6K +136.6K (+100.0%) | 0.10% +0.103 pp | 0.00% +0.001 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 19 | SQUAREPOINT OPS LLC | 16.7K +16.7K (+100.0%) | 132.6K +132.6K (+100.0%) | 0.10% +0.100 pp | 0.00% +0.000 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 20 | OCCUDO QUANTITATIVE STRATEGIES LP | 15.8K +15.8K (+100.0%) | 126.0K +126.0K (+100.0%) | 0.09% +0.095 pp | 0.01% +0.008 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 21 | MORGAN STANLEY | 14.6K +13.0K (+847.5%) | 115.8K +99.0K (+589.4%) | 0.09% +0.078 pp | 0.00% +0.000 pp | USD8.14 -2.2% | 11 qtrs — |
| 22 | MEYER HANDELMAN CO | 13.9K +— (+0.0%) | 110.6K -41.4K (-27.2%) | 0.08% -0.003 pp | 0.00% -0.001 pp | USD5.89 +35.1% | 11 qtrs — |
| 23 | JEFFERIES FINANCIAL GROUP INC. | 11.9K +6.7K (+129.7%) | 95.1K +38.2K (+67.1%) | 0.07% +0.039 pp | 0.00% +0.000 pp | USD9.26 -14.0% | 2 qtrs — |
| 24 | POINT72 ASSET MANAGEMENT, L.P. | 11.7K +11.7K (+100.0%) | 92.8K +92.8K (+100.0%) | 0.07% +0.070 pp | 0.00% +0.000 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 25 | HIGHTOWER ADVISORS, LLC | 11.2K +11.2K (+100.0%) | 89.0K +89.0K (+100.0%) | 0.07% +0.067 pp | 0.00% +0.000 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 26 | SUMMIT FINANCIAL, LLC | 10.0K +10.0K (+100.0%) | 79.7K +79.7K (+100.0%) | 0.06% +0.060 pp | 0.00% +0.001 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 27 | WILEY BROS.-AINTREE CAPITAL, LLC | 10.0K +— (+0.0%) | 79.6K -29.8K (-27.2%) | 0.06% -0.002 pp | 0.00% 0.000 pp | USD7.72 +3.1% | 3 qtrs — |
| 28 | MAYFLOWER FINANCIAL ADVISORS, LLC | 10.0K +— (+0.0%) | 79.6K -29.8K (-27.2%) | 0.06% -0.002 pp | 0.01% -0.004 pp | USD7.72 +3.1% | 3 qtrs — |
| 29 | MOODY LYNN & LIEBERSON, LLC | 10.0K +— (+0.0%) | 79.6K -29.8K (-27.2%) | 0.06% -0.002 pp | 0.00% -0.002 pp | USD6.16 +29.2% | 4 qtrs — |
| 30 | CIBC PRIVATE WEALTH GROUP, LLC | 7.0K +— (+0.0%) | 55.7K +13.2K (+30.9%) | 0.04% -0.002 pp | 0.00% +0.000 pp | USD7.12 +11.8% | 8 qtrs — |
| 31 | BNP PARIBAS ARBITRAGE, SNC | 5.7K +5.7K (+100.0%) | 45.1K +45.1K (+100.0%) | 0.03% +0.034 pp | 0.00% +0.000 pp | USD7.96 +0.0% | 5 qtrs — |
| 32 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 1.6K +— (+0.0%) | 12.4K -4.6K (-27.2%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD5.89 +35.1% | 11 qtrs — |
| 33 | BANK OF AMERICA CORP /DE/ | 1.2K -2.4K (-67.7%) | 9.2K -30.0K (-76.5%) | 0.01% -0.015 pp | 0.00% +0.000 pp | USD9.16 -13.1% | 11 qtrs — |
| 34 | FARTHER FINANCE ADVISORS, LLC | 705.00 +65.0 (+10.2%) | 5.6K -1.4K (-19.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD10.66 -25.3% | 2 qtrs — |
| 35 | GROUP ONE TRADING, L.P. | 323.00 +323.0 (+100.0%) | 2.6K +2.6K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 36 | ROYAL BANK OF CANADA | 219.00 +219.0 (+100.0%) | 2.0K +2.0K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 37 | WELLS FARGO & COMPANY/MN | 200.00 +— (+0.0%) | 1.6K -596.0 (-27.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD10.94 -27.2% | 2 qtrs — |
| 38 | FORTITUDE FAMILY OFFICE, LLC | 93.00 +93.0 (+100.0%) | 740.00 +740.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD7.96 +0.0% | 1 qtrs NEW |
| 39 | SBI SECURITIES CO., LTD. | 82.00 +— (+0.0%) | 653.00 -244.0 (-27.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.09 +56.4% | 5 qtrs — |
| 40 | CRESSET ASSET MANAGEMENT, LLC | — -26.9K (-100.0%) | — -294.6K (-100.0%) | 0.00% -0.168 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 41 | SIMPLEX TRADING, LLC | — -103.0 (-100.0%) | — -1.0K (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 42 | MILLENNIUM MANAGEMENT LLC | — -22.8K (-100.0%) | — -249.9K (-100.0%) | 0.00% -0.142 pp | 0.00% 0.000 pp | USD— | 4 qtrs SOLD |
| 43 | CITIGROUP INC | — -10.7K (-100.0%) | — -116.6K (-100.0%) | 0.00% -0.066 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 44 | CAPTION MANAGEMENT, LLC | — -105.0K (-100.0%) | — -1.1M (-100.0%) | 0.00% -0.654 pp | 0.00% -0.009 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 33 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 152.1K | 0.60% |
| 2 | iShares Russell 2000 Growth ETF IWO | 0.00% | 424.6K | 0.24% |
| 3 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.00% | 47.1K | 0.30% |
| 4 | Vanguard Extended Market ETF VXF | 0.00% | 1.41M | 0.05% |
| 5 | Global X - Russell 2000 ETF RSSL | 0.00% | 21.1K | 0.08% |
| 6 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.00% | 4.5K | 0.25% |
| 7 | iShares Russell 2000 BuyWrite ETF IWMW | 0.00% | 775.68 | 0.39% |
| 8 | iShares Russell 2000 ETF IWM | 0.00% | 1.13M | 0.19% |
| 9 | iShares U.S. Small Cap Index ETF (CAD-Hedged) XSU.TO | 0.00% | 7.4K | 0.36% |
| 10 | ProShares - Ultra Russell2000 UWM | 0.00% | 1.8K | 1.07% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
8
Sells
0
Shares acquired
431.4K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+431,400
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-02 | Shah Preetam | Officer | A-Award | A | Stock Option (Right to Buy) | 47,900 | 8.10 | 388.0K | 47,900 | D | ↗ |
| 2026-02-02 | Haqq Christopher | Officer | A-Award | A | Common Stock | 25,400 | 0.00 | — | 57,381 | D | ↗ |
| 2026-02-02 | DeMuth Peter | Officer | A-Award | A | Stock Option (Right to Buy) | 41,600 | 8.10 | 337.0K | 41,600 | D | ↗ |
| 2026-02-02 | Connelly Robert | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 147,200 | 8.10 | 1.19M | 147,200 | D | ↗ |
| 2025-12-09 | DeMuth Peter | Officer | M-Exempt | A | Common Stock | 362 | 4.41 | 1.6K | 743 | D | ↗ |
| 2025-06-03 | Chudnovsky Yekaterina | Director / 10% Owner | A-Award | A | Warrant (right to buy) | 103,225 | 7.75 | 800.0K | 103,225 | I | ↗ |
| 2025-05-19 | WILSON KAREN J | Director | A-Award | A | Stock Option (Right to Buy) | 7,900 | 5.84 | 46.1K | 7,900 | D | ↗ |
| 2025-05-19 | Venkatesan Jay | Director | A-Award | A | Stock Option (Right to Buy) | 7,900 | 5.84 | 46.1K | 7,900 | D | ↗ |
| 2025-05-19 | RUFFOLO ROBERT R | Director | A-Award | A | Stock Option (Right to Buy) | 7,900 | 5.84 | 46.1K | 7,900 | D | ↗ |
| 2025-05-19 | Nissenson Allen | Director | A-Award | A | Stock Option (Right to Buy) | 7,900 | 5.84 | 46.1K | 7,900 | D | ↗ |
| 2025-05-19 | Chudnovsky Yekaterina | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 7,900 | 5.84 | 46.1K | 7,900 | D | ↗ |
| 2025-05-19 | Ashe Carol Gail | Director | A-Award | A | Stock Option (Right to Buy) | 7,900 | 5.84 | 46.1K | 7,900 | D | ↗ |
| 2025-05-19 | ADAMS JULIAN | Director | A-Award | A | Stock Option (Right to Buy) | 7,900 | 5.84 | 46.1K | 7,900 | D | ↗ |
| 2025-04-15 | Shah Preetam | Officer | A-Award | A | Stock Option (Right to Buy) | 191,624 | 4.98 | 954.3K | 191,624 | D | ↗ |
| 2025-03-24 | Shah Preetam | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-03-05 | Chudnovsky Yekaterina | Director / 10% Owner | C-Conversion | A | Common Stock | 3,500,573 | 5.81 | 20.34M | 5,416,212 | I | ↗ |
| 2025-02-03 | Haqq Christopher | Officer | A-Award | A | Stock Option (Right to Buy) | 44,000 | 8.92 | 392.5K | 44,000 | D | ↗ |
| 2025-02-03 | DeMuth Peter | Officer | A-Award | A | Stock Option (Right to Buy) | 44,400 | 8.92 | 396.0K | 44,400 | D | ↗ |
| 2025-02-03 | Connelly Robert | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 121,600 | 8.92 | 1.08M | 121,600 | D | ↗ |
| 2024-12-16 | DeMuth Peter | Officer | M-Exempt | D | Stock Option (Right to Buy) | 381 | 4.41 | 1.7K | 0 | D | ↗ |
| 2024-11-26 | Venkatesan Jay | Director | X-InTheMoney | A | Common Stock | 50,000 | 0.01 | 500.00 | 179,581 | D | ↗ |
| 2024-11-21 | WILSON KAREN J | Director | A-Award | A | Stock Option (Right to Buy) | 4,100 | 5.12 | 21.0K | 4,100 | D | ↗ |
| 2024-11-21 | Venkatesan Jay | Director | A-Award | A | Stock Option (Right to Buy) | 4,100 | 5.12 | 21.0K | 4,100 | D | ↗ |
| 2024-11-21 | RUFFOLO ROBERT R | Director | A-Award | A | Stock Option (Right to Buy) | 4,100 | 5.12 | 21.0K | 4,100 | D | ↗ |
| 2024-11-21 | Nissenson Allen | Director | A-Award | A | Stock Option (Right to Buy) | 4,100 | 5.12 | 21.0K | 4,100 | D | ↗ |
| 2024-11-21 | Chudnovsky Yekaterina | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 4,100 | 5.12 | 21.0K | 4,100 | D | ↗ |
| 2024-11-21 | Ashe Carol Gail | Director | A-Award | A | Stock Option (Right to Buy) | 4,100 | 5.12 | 21.0K | 4,100 | D | ↗ |
| 2024-11-21 | ADAMS JULIAN | Director | A-Award | A | Stock Option (Right to Buy) | 4,100 | 5.12 | 21.0K | 4,100 | D | ↗ |
| 2024-09-30 | Haqq Christopher | Officer | A-Award | A | Stock Option (Right to Buy) | 28,200 | 5.03 | 141.8K | 28,200 | D | ↗ |
| 2024-09-30 | DeMuth Peter | Officer | A-Award | A | Stock Option (Right to Buy) | 29,800 | 5.03 | 149.9K | 29,800 | D | ↗ |
| 2024-09-30 | Connelly Robert | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 91,600 | 5.03 | 460.7K | 91,600 | D | ↗ |
| 2024-08-12 | Chudnovsky Yekaterina | Director / 10% Owner | P-Purchase | A | Convertible Note (convertible into Common Stock) | 3,442,341 | 5.81 | 20.00M | 3,442,341 | — | ↗ |
| 2024-06-28 | Venkatesan Jay | Director | P-Purchase | A | Common Warrants | 50,000 | 5.00 | 250.0K | 50,000 | — | ↗ |
| 2024-06-28 | Chudnovsky Yekaterina | Director / 10% Owner | P-Purchase | A | Common Warrants | 1,600,000 | 5.00 | 8.00M | 1,600,000 | — | ↗ |
| 2024-03-19 | Chudnovsky Yekaterina | Director / 10% Owner | P-Purchase | A | Pre-Funded Common Stock Purchase Warrant | 1,032,702 | 0.01 | 10.3K | 1,032,702 | — | ↗ |
| 2024-02-01 | Piekos Brian | Officer | A-Award | A | Stock Option (right to buy) | 43,225 | 4.50 | 194.5K | 43,225 | — | ↗ |
| 2024-02-01 | Haqq Christopher | Officer | A-Award | A | Stock Option (right to buy) | 28,200 | 4.50 | 126.9K | 28,200 | — | ↗ |
| 2024-02-01 | DeMuth Peter | Officer | A-Award | A | Stock Option (right to buy) | 29,800 | 4.50 | 134.1K | 29,800 | — | ↗ |
| 2024-02-01 | Connelly Robert | Director / Officer | A-Award | A | Stock Option (right to buy) | 225,137 | 4.50 | 1.01M | 225,137 | — | ↗ |
Executive team
Top executives
Shares Outstanding
18.70M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2023 | Jay R. Venkatesan, M.D. former Chief Executive Officer, President, and Chairman of the Angion Board | 243.9K | 608.0K | — | 22.4K | — | 1.55M | 2.43M | 0.92% | ↗ |
| 2 | 2023 | Jennifer J. Rhodes former Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Corporate Secretary | 222.3K | 440.8K | — | — | — | 702.8K | 1.37M | 0.00% | ↗ |
| 3 | 2023 | Brian Piekos former Chief Financial Officer and Treasurer | 273.5K | — | — | 502.0K | 103.2K | — | 878.8K | 57.12% | ↗ |
| 4 | 2023 | Robert Connelly President, Chief Executive Officer, and Director | 498.8K | — | — | — | 179.6K | — | 678.3K | 0.00% | ↗ |
| 5 | 2023 | Christopher Haqq, M.D., Ph.D., Executive Vice President, Head of Research and Development and Chief Medical Officer | 488.3K | — | — | — | 185.5K | — | 673.8K | 0.00% | ↗ |
| 6 | 2022 | Jay R. Venkatesan, M.D. former Chief Executive Officer, President, and Chairman of the Angion Board | 608.0K | — | — | 899.0K | 11.9K | — | 1.52M | 59.19% | ↗ |
| 7 | 2022 | Robert Connelly President, Chief Executive Officer, and Director | 475.0K | — | — | 572.0K | 209.0K | — | 1.26M | 45.54% | ↗ |
| 8 | 2022 | Christopher Haqq, M.D., Ph.D., Executive Vice President, Head of Research and Development and Chief Medical Officer | 465.0K | — | — | 511.3K | 186.0K | — | 1.16M | 43.99% | ↗ |
| 9 | 2022 | Jennifer J. Rhodes former Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Corporate Secretary | 440.8K | — | — | 320.6K | 12.2K | — | 773.7K | 41.44% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Robert T. Connelly | Chief Executive Officer, President & Director | 980.7K | male |
| Christopher Haqq | Executive Vice President, Head of Research & Development and Chief Medical Officer | 750.0K | — |
| Preetam Shah | Chief Strategy & Financial Officer and Treasurer | 687.1K | — |
| Peter DeMuth | Chief Scientific Officer | 648.6K | — |
| Allen Richard Nissenson FACP | Founder & Independent Director | 52.5K | — |
| Megan C. Filoon | General Counsel, Secretary & Compliance Officer | — | female |
| Thian Kheoh | Senior Vice President of Biometrics | — | — |
| Darrell J. Irvine | Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board | — | — |
| Esther Welkowsky | Senior Vice President of Clinical Development | — | female |
| Joy Seymour | Vice President & Head of Regulatory Affairs | — | female |
| Marc J. Wolfgang | Chief Technology Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ELTX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
